Literature DB >> 33903101

In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Dae Hun Kim1, Su-Young Kim1, Won-Jung Koh1, Byung Woo Jhun1.   

Abstract

We evaluated the in vitro activities of oxazolidinone antibiotics, including linezolid, sutezolid, and delpazolid, against clinical nontuberculous mycobacteria (NTM) isolates. Regardless of macrolide resistance, for Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium kansasii, sutezolid showed the lowest MIC and minimal bactericidal concentration (MBC) values among oxazolidinone antibiotics. However, for Mycobacterium abscessus and Mycobacterium massiliense, the MIC and MBC for all oxazolidinone antibiotics showed similar values. Oxazolidinone antibiotics warrant further investigation as potential treatment for NTM.

Entities:  

Keywords:  Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium kansasii; nontuberculous mycobacteria; oxazolidinone

Mesh：

Substances：

Year:  2021        PMID： 33903101      PMCID： PMC8218642          DOI： 10.1128/AAC.02306-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

3.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype.

Authors:  Won-Jung Koh; Seong Mi Moon; Su-Young Kim; Min-Ah Woo; Seonwoo Kim; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Myung Jin Chung; Kyung Soo Lee; Sung Jae Shin; Charles L Daley; Hojoong Kim; O Jung Kwon
Journal:  Eur Respir J       Date:  2017-09-27       Impact factor: 16.671

Review 4.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

5.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 6.  Update on pulmonary disease due to non-tuberculous mycobacteria.

Authors:  Jason E Stout; Won-Jung Koh; Wing Wai Yew
Journal:  Int J Infect Dis       Date:  2016-03-11       Impact factor: 3.623

Review 7.  Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.

Authors:  W-J Koh; J E Stout; W-W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

8.  Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review.

Authors:  Roland Diel; Albert Nienhaus; Felix C Ringshausen; Elvira Richter; Tobias Welte; Klaus F Rabe; Robert Loddenkemper
Journal:  Chest       Date:  2018-02-02       Impact factor: 9.410

9.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors:  Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

10.  Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic.

Authors:  Jung Sunwoo; Yu Kyong Kim; Yewon Choi; Kyung-Sang Yu; Heesook Nam; Young Lag Cho; Seonghae Yoon; Jae-Yong Chung
Journal:  Drug Des Devel Ther       Date:  2018-06-11       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.